Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.

Name: Αlpha¹ Rigor Record — Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.
Item: Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.
Rating: 100
Author: Αlpha¹

Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Yawe I, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Okwero M, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI, CARES trial team

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 2 high issues for “Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 24 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 3b randomized noninferiority trial. The paper demonstrates strong scientific premise, rigorous design, comprehensive reporting of biological variables, ethical approvals, key resources, statistical methods, data availability, and transparency. Minor reporting gaps include unspecified randomization method and placeholder accession numbers.

Both reviewers independently scored all eight dimensions and agreed on all statuses. The study type is interventional (randomized controlled trial). Non-applicable sub-criteria (e.g., animal-related, cell line authentication) were excluded from scoring. The statistics verification covered only a subset of reported tests; no errors were found, but this does not constitute a full validation.

9 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites WHO recommendations and prior registrational trials of cabotegravir/rilpivirine, noting they were conducted mainly in Europe and North America. It explicitly states that evidence in Africa is limited to one trial (this trial) and that longer-term follow-up is needed, providing a logical rationale for the 96-week analysis. The paper addresses limitations of prior work by highlighting the need for data in a population with high proportions of women and Black participants, NNRTI exposure, and African viral subtypes.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on long-acting therapy and identifying the evidence gap in African populations.

Evidence

direct quote[Introduction, paragraph 1]

“A two-drug regimen of cabotegravir (an integrase inhibitor) and rilpivirine (a non-NRTI, NNRTI) given by intramuscular injection once every 4 or 8 weeks, has been shown to maintain viral suppression and to increase treatment satisfaction in participants switching from standard therapy in registrational trials done mainly in Europe and North America”